If this observation can (i) be validated in an in vivo animal model and (ii) be demonstrated in human biopsies, for example, in the form of VGSC + EGF/EGF receptor (EGFR) co-localization, it could form the basis of a novel therapy of NSCLC, for example, combining an EGFR tyrosine kinase inhibitor with a VGSC blocker. The gene discussed is EGF; the disease is non-small cell lung carcinoma.